Regulus Therapeutics (RGLS) shares were down 21% in recent trading Wednesday even after the company said that a portion of subjects benefited from farabursen in an early-stage study.
Interim results from the fourth cohort of subjects enrolled in the company's phase 1b study of farabursen found that patients with autosomal dominant polycystic kidney disease, or ADPKD, responded to the treatment.
The interim data was based on the first 14 subjects of the cohort who also saw a "notable reduction" in height-adjusted total kidney volume growth rate, the company said.
Additionally, all 26 subjects in the cohort demonstrated that farabursen was well tolerated, according to Regulus.
Meanwhile, the company said it had successfully concluded a meeting with the US Food and Drug Administration in December, reaching an agreement on the design of a phase 3 trial of farabursen.
Price: 0.92, Change: -0.25, Percent Change: -21.03
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。